Back to search results

18F-FSPG PET Imaging for Hepatocellular Carcinoma

This study is for people with hepatocellular carcinoma (HCC), a type of liver cancer. It aims to see if a special imaging test using an injected substance called 18F-FSPG (a radiopharmaceutical) can help predict how well your cancer will respond to Y90 radioembolization therapy. Researchers will also look at how changes in 18F-FSPG uptake in your tumors relate to changes in circulating tumor DNA (ctDNA) in your blood and your response to treatment. The study will also evaluate if 18F-FSPG PET can find any remaining cancer after treatment. You may be able to join if you are 18 or older and have been diagnosed with HCC based on specific imaging features. The study plans to enroll 60 participants.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 60 participants.
What's involved
You will receive an injection of 18F-FSPG for imaging. Researchers will also collect blood samples to measure ctDNA before and after Y90 radioembolization.
Compensation
Not stated in the trial record.
Follow-up
Your safety and side effects will be monitored throughout the study, which is expected to last an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07116486

A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma

Recruiting
PHASE1Ages 18+InterventionalDiagnostic
M.D. Anderson Cancer Center
~60 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Radiopharmaceutical 18F-FSPG

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Hepatocellular Carcinoma

Explore related trials

Hepatocellular Carcinoma

NCT07116486

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Simone Krebs, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Simone Krebs, MD
[email protected]
(713) 563-6726
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Postmenopausal (no menses in greater than or equal to 12 consecutive months).
History of hysterectomy or bilateral salpingo-oophorectomy.
Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
History of bilateral tubal ligation or another surgical sterilization procedure.
Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of 18F-FSPG administration. 6. Ability to understand and the willingness to sign a written informed consent document

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0